

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

NCT06517888

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Akouos, Inc.
Enrollment	27 participants

Key Eligibility Criteria

Inclusion (4)

- Presence of unilateral, progressive vestibular schwannoma.
- Vestibular schwannoma larger than 2 mm.
- Profound hearing loss, defined by pure-tone audiometry thresholds or word recognition score, in the affected ear.
- Able and willing to comply with all trial requirements, including willingness to participate in a separate long term follow-up study after completion of this trial.

Exclusion (5)

- Prior diagnosis of NF2 and/or bilateral vestibular schwannoma.
- Prior surgery or radiation therapy for vestibular schwannoma.
- Clinical history consistent with endolymphatic hydrops (documented fluctuating sensorineural hearing loss and/or episodic vertigo) in the affected ear.
- Profound hearing loss, defined by pure-tone audiometry thresholds or word recognition score, in the unaffected ear.
- Prior participation in a clinical trial with an investigational drug within six months prior to administration (Day 0), or any prior participation in a gene therapy clinical trial.

Locations (4 total)

Johns Hopkins Hospital, Baltimore, Maryland, United States
Mayo Clinic, Rochester, Minnesota, United States
Vanderbilt Bill Wilkerson Center, Nashville, Tennessee, United States
... and 1 more locations